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Here we show that 14-3-3 proteins bind to Pim kinase-phosphorylated Ser166 and Ser186 on the
human E3 ubiquitin ligase mouse double minute 2 (Mdm2), but not protein kinase B (PKB)/
Akt-phosphorylated Ser166 and Ser188. Pim-mediated phosphorylation of Ser186 blocks phosphor-
ylation of Ser188 by PKB, indicating potential interplay between the Pim and PKB signaling path-
ways in regulating Mdm2. In cells, expression of Pim kinases promoted phosphorylation of Ser166
and Ser186, interaction of Mdm2 with endogenous 14-3-3s and p14ARF, and also increased the
amount of Mdm2 protein by a mechanism that does not require Pim kinase activities. The implica-
tions of these ﬁndings for regulation of the p53 pathway, oncogenesis and drug discovery are dis-
cussed.
Structured summary:
MINT-6823587: PIM3 (uniprotkb:Q86V86) phosphorylates (MI:0217) MDM2 (uniprotkb:Q00987) by pro-
tein kinase assay (MI:0424)
MINT-6823623: MDM2 (uniprotkb:Q00987) physically interacts (MI:0218) with p14ARF (uni-
protkb:Q8N7268N726) by coimmunoprecipitation (MI:0019)
MINT-6823537: PKB (uniprotkb:P31749) phosphorylates (MI:0217)MDM2 (uniprotkb:Q00987) by protein
kinase assay (MI:0424)
MINT-6823574: PIM2 (uniprotkb:QP1W9) phosphorylates (MI:0217) MDM2 (uniprotkb:Q00987) by pro-
tein kinase assay (MI:0424)
MINT-6823555: PIM1 (uniprotkb:P11309)P phosphorylates (MI:0217) MDM2 (uniprotkb:Q00987) by pro-
tein kinase assay (MI:0424)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumor suppressor p53 is commonly deregulated in tumors
by mutation or deletion of p53 itself, and/or upregulation of mouse
double minute 2 (Mdm2), an E3 ubiquitin ligase that targets p53
and other proteins for proteasomal degradation and also inhibits
p53-dependent transcription [1,2]. Mdm2 is regulated by multisite
phosphorylation [3–5], including phosphorylation of Ser166,
Ser186 and Ser188 (RRRAIS166ETEENSDELSGERQRKRHKS186DS188-
ISLSFDESLAL) that are variously reported to be phosphorylatedchemical Societies. Published by E
ES, nuclear export sequence;
B (also known as Akt); PP2A,
osh).by protein kinase B (PKB)/Akt, and clustered around a bipartite
nuclear localization sequence (NLS), residues 178–184 [6], and an
nuclear export sequence (NES), residues 190–199 [7]. These phos-
phorylations reportedly promote nuclear entry, allowing Mdm2
access to nuclear p53 [8–10]. The Mdm2/p53 complex is thought
to shuttle back out to the cytoplasm for proteasomal degradation
of p53 [7,11].
Protein phosphorylation by PKB/Akt sometimes creates sites for
binding to 14-3-3s, a family of dimeric proteins that dock onto spe-
ciﬁc phosphorylated residues and change their targets’ activities
and interactions with other proteins [12]. Their dimeric structure
allows 14-3-3s to bind simultaneously to two phosphorylated sites
a minimum of 15 residues apart. These considerations prompted
us to test whether a 14-3-3 dimer might bind two of the reported
PKB-phosphorylated residues at Ser166, Ser186 and/or Ser188
on human Mdm2. We found that 14-3-3s do indeed bindlsevier B.V. All rights reserved.
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PKB phosphorylation, which we observe in vitro on Ser166 and
Ser188, but by phosphorylation by oncogenic Pim kinases, which
phosphorylate Ser166 and Ser186 [13]. In vivo, Pim kinases stabi-
lize Mdm2 and promote phosphorylation-dependent interaction
with endogenous 14-3-3s and p14ARF.2. Materials and methods
2.1. Materials
Protein G-Sepharose was from GE Healthcare, tissue culture re-
agents from Biowhittaker and Life Technologies, pre-cast 4–12%
polyacrylamide Bis–Tris gels and associated buffers from Invitro-
gen. Unless stated, other chemicals were from Sigma–Aldrich or
BDH. Mouse monoclonal SMP14 to detect Mdm2 and rabbit anti-
p14ARF were from Abcam, mouse anti-GST was from Sigma and
K19 pan anti-14-3-3 from Santa Cruz. Phosphospeciﬁc antibodies
to Mdm2 were described previously [5].
2.2. General methods and buffers
DNA constructs for transfection of human cells were puriﬁed
from transformed Escherichia coli DH5a using Qiagen Mega
plasmid puriﬁcation kits. Lysis buffer contained 50 mM Tris–HCl
pH 7.5, 1 mM EGTA, 1 mM EDTA, 1% (w/v) Triton X-100, 1 mM
sodium orthovanadate, 50 mM sodium ﬂuoride, 5 mM sodium
pyrophosphate, 0.27 M sucrose, 0.1% (v/v) 2-mercaptoethanol
and one ‘Complete’ protease inhibitor tablet (Roche) per 50 ml.
TBS contained 50 mM Tris–HCl pH 7.5, 500 mM NaCl (with 0.1%
(v/v) Tween-20 included for TBS-T). Protein phosphatase 2A
(PP2A) was puriﬁed from bovine cardiac muscle by Julie Diplexcito
and Jean Harthill.
2.3. Plasmids
Human Pim-1 and Pim-2 mammalian expression constructs and
murine Pim-3 constructs for mammalian and baculovirus expres-
sion were described previously [14], as were constructs for
bacterial expression of glutathione S-transferase (GST)-Mdm2
mini-proteins [15]. The construct to express Mdm2 (NCBI Acc.
BT007258) as an HA-tagged protein in mammalian cells was
prepared by subcloning an EcoR1 fragment from a full-length clone
of Mdm2 in pCDNA3 into pCMV5.HA2. Mutations were introduced
using KOD Hot Start DNA polymerase (Novagen). DNA was
sequenced by The Sequencing Service, University of Dundee
(www.dnaseq.co.uk).
2.4. Enzymes and kinase assays
GST-Pim-1 and GST-Pim-2 proteins were puriﬁed from
lysates of transfected HEK293 cells by binding to glutathione-
Sepharose (Amersham Biosciences), washing extensively in wash
buffer (50 mM Tris–HCl pH 7.5, 250 mM NaCl, 0.03% Brij-35,
0.1 mM EGTA, 0.1% 2-mercaptoethanol, 0.2 mM PMSF, 1 mM
benzamidine), and eluting in wash buffer containing 20 mM
glutathione. His-tagged Pim-3 and PKB/Akt (His-PKBa-S473D;
residues 118–480 of the human protein) were puriﬁed in the
Division of Signal Transduction Therapy from Sf9 insect cells on
Ni-NTA-Sepharose using standard techniques. PKB was activated
by PDK1 (phosphoinositide-dependent kinase 1). The standard
substrate used to assay the Pim kinases was RSRMSSYPDRG
(derived from murine Bad) as described [14]. PKB was assayed
against Crosstide (GRPRTSSFAEG). One mU of activity is theamount that catalyzes phosphorylation of 1 nmol peptide sub-
strate in 1 min at 30 C.
2.5. Substrate puriﬁcation and in vitro phosphorylation
GST-Mdm2 mini-proteins were overexpressed in E. coli BL21
cells (Life Technologies) by induction with 50–250 lM isopropyl-
ß-D-thiogalactopyranoside at 26 C for 16 h. Cells were sonicated,
lysates centrifuged and GST-fusion proteins puriﬁed as described
above. Puriﬁed proteins were dialyzed against 50 mM Tris–HCl
pH 7.5, 0.1 mM EGTA, 250 mM NaCl, 0.1% 2-mercaptoethanol,
270 mM sucrose, 0.03% Brij-35, 1 mM benzamidine, 0.2 mM PMSF
overnight at 4 C and their identity conﬁrmed by tryptic mass ﬁn-
gerprinting [16] and Western blotting. Puriﬁed proteins (2 lg)
were phosphorylated in vitro with 400 mU/ml Pim kinases and
1 U/ml PKB/Akt in 50 mM Tris–HCl pH 7.5, 1 mM EDTA pH 7.9,
0.1% (v/v) 2-mercaptoethanol. Reactions were performed at 30 C
for 30 min unless otherwise stated and terminated by addition of
LDS sample buffer.
2.6. Cell culture, lysis and immunoprecipitation
Human embryonic kidney (HEK) 293 cells (European Collection
of Cell Cultures) were maintained in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% (v/v) fetal bovine serum. Cells
were cultured on 10 cm diameter dishes and split to 10–20% con-
ﬂuency the day prior to transfection. Cells were transiently trans-
fected with 5–10 lg plasmid DNA per dish using the DNA/
calcium phosphate co-precipitation method [17] and maintained
in 5% CO2 at 37 C for 16–30 h. Cells were serum starved for 5 h
(down-regulating the PKB pathway; Pim kinases remain active in
serum starved cells [14]) before lysis in 0.5–1 ml of ice-cold lysis
buffer. Lysates were clariﬁed by centrifugation at 13000g for
10 min at 4 C. For immunoprecipitations, 10 lg antibody was cou-
pled to Protein G-Sepharose (30 ll of 50% slurry in PBS) by mixing
for 1 h, and lysate (4 mg) added and mixed for 2 h at 4 C. Cells
were washed twice with TBS and twice with 50 mM Tris–HCl pH
7.5, 1 mM EDTA, 0.1% (v/v) 2-mercaptoethanol, pelleting Sepharose
in between washes.
2.7. Western blotting and 14-3-3 overlays
Proteins separated by SDS–PAGE were transferred to nitrocellu-
lose by wet electroblotting and processed for ECL detection (En-
hanced Chemiluminescent reagent; Amersham Biosciences) with
HRP-conjugated secondary antibodies (SMP14 immunoblots) or
Odyssey Infrared Imaging (LiCor) with AlexaFluor or IR Dye conju-
gates. Membranes were blocked in 5% Marvel milk powder/TBS
prior to detection. Commercial antibodies were used according to
the manufacturer’s instructions, diluted in 1% Marvel/TBS-T. Phos-
phospeciﬁc antibodies were used as in [5]. Mouse anti-HA was
used at 0.5 lg/ml and K19 (anti-14-3-3) at 1 lg/ml. 14-3-3 Over-
lays measure direct binding of digoxygenin-labeled 14-3-3 to
phosphorylated target proteins on a nitrocellulose membrane,
and were performed as previously described [12].
3. Results
3.1. Phosphorylation by Pim kinases but not PKB promotes 14-3-3
binding to Mdm2 in vitro
GST-fusions of four ‘mini-proteins’ spanning the functional
domains of Mdm2 (termed MP1 [Mdm2 residues 1–110], MP2
[108–200], MP3 [196–282] and MP4 [276–491]) were phosphory-
lated in vitro with PKB, Pim-1, Pim-2 and Pim-3. None were able to
Fig. 1. GST-Mdm2 MP2 phosphorylated in vitro by Pim-1 binds 14-3-3s: (a) schematic representation showing full-length mouse double minute 2 (Mdm2) and the four GST-
Mdm2 mini-proteins (MP1–4) used as substrates and (b) 14-3-3 Overlays of Mdm2 mini-proteins dephosphorylated by protein phosphatase 2A (PP2A) (50 mU/ml) and
phosphorylated in vitro by the kinases indicated. Except for the ﬁrst lane (no treatment), other substrates were pre-incubated with protein phosphatase 2A at 30 C for 30 min
and the reaction stopped by adding 50 lM microcystin-LR, prior to adding 10 mM MgAcetate/0.1 mM ATP and the kinase indicated and incubating for a further 30 min at
30 C. Phosphorylation reactions were stopped by the addition of LDS sample buffer.
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did bind PKB-phosphorylated E3 ubiquitin ligase Nedd4-2
(Fig. 1). In contrast, phosphorylation by any of the three Pim
kinases promoted 14-3-3 binding to GST-mini-protein 2, which
harbors the serine-ﬂanked NLS and NES motifs.
3.2. PKB and Pim kinases differentially phosphorylate serine residues
ﬂanking the NLS
Using phosphospeciﬁc antibodies [5], PKB and Pim-1 were both
found to phosphorylate Ser166, and PKB also phosphorylated
Ser188 whereas Pim-1 phosphorylated Ser186 (Fig. 2a). Binding
of 14-3-3s was observed speciﬁcally after incubation with PimFig. 2. Identiﬁcation of phosphorylation sites required for 14-3-3 binding: phosphospeciﬁc i
by (a) protein kinase B (PKB) or Pim-1, (b) wild-type or kinase-dead Pim kinases, (c) Pim
and alanine substitution mutants after in vitro phosphorylation with Pim-1. Mdm2 is shkinases and was phosphorylation-dependent, as no interaction
was observed with kinase-dead Pim-1 or Pim-2 (kinase-dead
Pim-3 was unavailable at the time of study) (Fig. 2b). While all
three Pim kinases phosphorylate Ser166 and Ser186, consistent
with recent ﬁndings [13], Pim-3 also phosphorylated Ser188
(Fig. 2b). Together, these data indicate that phosphoSer186 is
essential for 14-3-3 binding and explain why PKB is not able to
promote this interaction.
In an in vitro time course, Ser186 was maximally phosphory-
lated by Pim-1 within 1 min, whereas phosphorylation of Ser166
and 14-3-3 binding both increased gradually over 30 min
(Fig. 2c). Both phosphoSer166 and phosphoSer186 are required
for optimal 14-3-3 binding, as the interaction was signiﬁcantlymmunoblots and 14-3-3 overlays of GST-Mdm2-MP2 after phosphorylation in vitro
-1, with reactions terminated at the time points indicated, and (d) GST-Mdm2-MP2
own as a loading control.
Fig. 4. Co-expression with Pim-1 leads to elevated levels of HA-Mdm2 in cells: Western
blots showing recombinant Pim-1 and Mdm2 levels in lysates of HEK293 cells that
were transfected to express HA-Mdm2 alone (wild-type or alanine substitution
mutants), or HA-Mdm2 plus wild-type or kinase-dead GST-Pim-1. Similarly,
enhanced Mdm2 protein levels were seen for cells that co-expressed FLAG-tagged
Pim kinases (wild-type and kinase-dead), but not cells that co-expressed GST (data
not shown).
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Intriguingly, when Ser186 could not be phosphorylated (in
mutants harboring the Ser186Ala substitution), Pim-1 weakly
phosphorylated Ser188, although this did not compensate for the
lack of phosphoSer186 with respect to 14-3-3 binding.
3.3. Phosphorylation of Ser186 by Pim-1 blocks subsequent
phosphorylation of Ser188 by PKB
In vitro phosphorylation of GST-mini-protein 2 with Pim-1
blocked subsequent phosphorylation of Ser188 by PKB (Fig. 3a).
This was speciﬁcally due to phosphorylation of Ser186 since the
Ser186Ala mutant (phosphorylated at Ser166) could still be phos-
phorylated by PKB at Ser188. However, when Ser166 and Ser188
were ﬁrst phosphorylated by PKB, Pim-1 could still phosphorylate
Ser186 (Fig. 3b).
3.4. Expression of Pim kinases stabilizes Mdm2 in vivo but binding to
endogenous 14-3-3s and p14ARF is phosphorylation-dependent
Pim kinases are controlled by regulated expression of the con-
stitutively active enzymes [18]. The stimuli that induce Pim kinase
expression in vivo also trigger more-widespread changes however.
Therefore, to test the speciﬁc effects of Pim kinases on Mdm2 in
vivo, constructs encoding wild-type or kinase-dead (inactive) Pim
kinases were co-expressed in HEK293 cells alongside full-length
Mdm2. Strikingly, Pim kinase expression induced a signiﬁcant in-
crease in the levels of Mdm2 protein (Fig. 4), an effect that was
independent of phosphorylation at Ser166 and Ser186 since it
was observed with Mdm2 mutants harboring Ser to Ala substitu-
tions at these positions and upon co-expression of both kinase-
dead and wild-type Pim kinases. 14-3-3 binding however, was
phosphorylation-dependent; phosphospeciﬁc antibodies revealed
that only Mdm2 co-expressed with active, wild-type Pim kinases
was phosphorylated on Ser166 and Ser186 and endogenous 14-
3-3s co-puriﬁed speciﬁcally with Pim-phosphorylated wild-type
Mdm2 (Fig. 5). We also checked whether other known interactors
of Mdm2 (including p53, the transcriptional co-activator p300, the
Mdm2-related protein MdmX and the tumor suppressor p14ARF)Fig. 3. Sequential phosphorylation of MP2 by PKB and Pim kinases: residues
phosphorylated in vitro by either (a) Pim-1 followed by PKB or (b) PKB followed
by Pim-1. Reactions were started with the ﬁrst kinase for 30 min followed by the
second kinase for a further 30 min.
Fig. 5. Interaction of Mdm2 with 14-3-3s and p14ARF is phosphorylation-dependent: (a)
phosphospeciﬁc immunoblots and 14-3-3 overlay of HA-Mdm2 immunoprecipi-
tated from extracts of transfected HEK293 cells co-expressing either wild-type or
kinase-dead Pim-1 and (b) Western blots of endogenous 14-3-3s and p14ARF in anti-
HA immunoprecipitates extracts of from transfected HEK293 cells co-expressing
wild-type or double alanine mutant HA-Mdm2 with wild-type or kinase-dead
Pim-1.
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found that p14ARF selectively co-puriﬁed with Pim-phosphorylated
wild-type Mdm2 (Fig. 5).
4. Discussion
Our ﬁndings connect three types of signaling component,
Mdm2, Pim kinases and 14-3-3 proteins, which are each linked
to the p53 pathway and cancers. Pim kinases are overexpressed
in hematological malignancies and other cancers, with impacts
on Mdm2 and the p53 pathway [13]. 14-3-3s have central regula-
tory roles in processes that are deregulated in cancers. Generally,
14-3-3/target interactions promote cell survival events and several
14-3-3 isoforms are overexpressed in various tumors. In contrast,
the 14-3-3sigma isoform is frequently deleted in tumors, and has
special roles in DNA damage responses, inhibits cell cycle progres-
sion, and is a p53-inducible gene [19,20]. Recently, 14-3-3sigma
was reported to bind to the ring domain of Mdm2, destabilize
Mdm2 and promote its cytoplasmic localization, thereby stabiliz-
ing p53 [21]. 14-3-3sigma is not present in the HEK293 cells used
in our study, though these cells do contain the other six 14-3-3
isoforms (theta, gamma, beta, eta, zeta, epsilon) [22]. It will be
important to determine the selectivity of 14-3-3 isoforms for bind-
ing to the ring domain [21] and Pim-phosphorylated Ser166 and
Ser186 (this study). 14-3-3s have also been reported to impact
on Mdm2 levels by binding to PKB/Akt-phosphorylated sites on
MdmX, which stabilizes MdmX itself and also Mdm2 [23].
A recent study [24] set a precedent for Pim-mediated phosphor-
ylation and 14-3-3-binding of residues ﬂanking an NLS on the
cyclin-dependent kinase inhibitor p27KIP1, inhibiting NLS binding
to the importins required for nuclear import. Whether 14-3-3
binding to Pim-phosphorylated pSer166 and pSer186 on Mdm2
inﬂuences its subcellular localization remains to be determined.
For Mdm2, it is PKB/Akt that has been proposed to play a role in
translocating Mdm2 to the nucleus in order to down-regulate
p53 [8–10]. Although there is general consensus that PKB/Akt
phosphorylates Mdm2 at Ser166 [8–10,25], the second PKB/Akt
site has been proposed to be either Ser186 [9,10] or Ser188
[5,25]. While we conﬁrm Ser166 and Ser188 as in vitro PKB/Akt
sites, we failed to detect phosphoSer188 on tagged Mdm2 under
conditions where other PKB/Akt substrates were phosphorylated
in cells (not shown), which could, perhaps, be due to hierarchical
interactions between phosphorylated sites on Mdm2. For example,
here we found that phosphorylation of Ser186 by Pim-1 in vitro
blocks subsequent phosphorylation of Ser188 by PKB/Akt. This
observation is noteworthy in view of the proximity of sites phos-
phorylated by Pim kinases and PKB, both to each other, and to
functional motifs governing subcellular localization. Indeed, it is
tempting to speculate that any interplay between these pathways
(one leading to 14-3-3 binding, one not) may represent a potential
regulatory switch controlling nucleo-cytoplasmic shuttling of
Mdm2.
Here, Pim-phosphorylated Mdm2 speciﬁcally co-puriﬁed not
only 14-3-3s, but also the tumor suppressor p14ARF. ARF sup-
presses aberrant cell growth in response to oncogenic stimulation
by various antagonistic interactions that release p53 from the
inhibitory effects of Mdm2, directly inhibiting Mdm2 ubiquitin
ligase [26,27], and, in certain circumstances, sequestering Mdm2
in the nucleolus [11,28]. ARF binding also stabilizes Mdm2 [29]
and is required for the Pim-induced upregulation of Mdm2
observed by Hogan et al. [13]. While our coimmunoprecipitation
data are not inconsistent with the hypothesis that expression of
the Pim-1 oncogene induces ARF and that ARF is required for
increased Mdm2 expression/stability, we ﬁnd that ARF co-puriﬁes
speciﬁcally with Mdm2 co-expressed with wild-type Pim-1 eventhough Mdm2 levels are increased by co-expression of both
wild-type or kinase-dead (inactive) Pim-1. We suggest therefore
that this up-regulatory effect may be independent of Pim-1 phos-
phorylation at Ser166 and Ser186 and ARF binding to Mdm2; it
is also independent of transcriptional feedback control from other
components of the p53 pathway since it is observed even when
Mdm2 is expressed from a heterologous promoter. The functional
signiﬁcance of ARF binding speciﬁcally to Pim-phosphorylated
Mdm2, and indeed the precise role of 14-3-3s in this complex
therefore, remain to be determined.
Finally, ﬁnding that both wild-type and kinase-dead Pims pro-
mote elevated levels of Mdm2 in cells ([13] and this study) has
implications for the Pim kinases as a drug targets for hematological
malignancies. Clearly, it will be critical to determine whether or
not drug-inhibited Pims can also elevate cellular Mdm2 levels.
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